Lung Cancer Vaccine
1,980 viewsThe health authorities of Cuba in Peru registered a therapeutic vaccine against lung cancer that has been applied with favorable results in about 2,000 patients. The news was released on Tuesday by state-run newspaper “Granma,” the Communist Party.
CimaVax-EGF vaccine offers the possibility of converting advanced cancer in a manageable chronic illness, the newspaper said. It began to be marketed on the island earlier this year after being tested in more than one thousand patients without causing severe side effects.
<"The Up-Vax EFG is registered in Cuba and Peru, and has patent rights in most of the world," said Gisela Gonzalez, head of the team developing the vaccine, cited by "Granma."
According to the Cuban press, the registration process was underway in other Latin American countries.
Gonzalez said that clinical trials with the Cima Vax EGF-started in 1995 and have "demonstrated safety and immune response" in patients in advanced stages of disease.
Cancer is a leading cause of death in Cuba. In 2010, there were more than 22 000 deaths oncogenic tumors - including almost 12 000 women, according to official figures.
The vaccine is applied to lung cancer in patients receiving radiation treatments or chemotherapy to control tumor growth without toxicity associated with the expert explained, the paper said.
The Cuban biotechnology industry represents a significant injection of foreign currency to the weak domestic economy, with the marketing of 38 drugs in about 40 countries.
According to recent figures, biotechnology generates entries that exceed the annual $ 300 million.
The Cuban authorities are driving the technological cooperation, for example, with China, its second trade partner.
In late November, Havana and Beijing signed several agreements for the development of vaccines, by promoting the bilateral five-year period 2012-2016.
The announcement that works in clinical trials for a vaccine against prostate cancer. Cuba has manufactured a drug against cervical cancer and a recombinant cardiovascular problems.